Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Immunoglobulin G4 (IgG4)-related disease is a fibroinflammatory condition involving diverse organs. We report a case of IgG4-related pancreatitis and retroperitoneal fibrosis with serial 68Ga-FAPI PET/CT scans after treatment. A 64-year-old man presented with left flank and epigastric pain. Laboratory, abdominal CT, and 68Ga-FAPI PET/CT findings were suggestive of IgG4-related pancreatitis and retroperitoneal fibrosis. Histology of the pancreas confirmed IgG4-related pancreatitis. The follow-up PET/CT scans after treatment with steroid therapy showed regression of 68Ga-FAPI uptake in the pancreas and periureteral soft tissue. The changes on 68Ga-FAPI PET/CT scans were much more prominent compared with the CT scans.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/RLU.0000000000004793 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Increased 68Ga-FAPI Uptake of Ureteric Fibroepithelial Polyp and Costal Cyst Mimicking Malignancy With Bone Metastasis.
Clin Nucl Med
September 2025
Departments of Nuclear Medicine, Affiliated Hospital of Inner Mongolia Medical University.
A 70-year-old man presented with progressive dysuria. 18F-FDG PET/CT showed no abnormal metabolic activity. 68Ga-FAPI PET/CT revealed intense 68Ga-FAPI in the lower left ureter and the left rib, mimicking malignancy with bone metastasis.
View Article and Find Full Text PDFComparison of 68Ga-FAPI-04 and 18F-FDG in Primary Splenic Angiosarcoma.
Clin Nucl Med
September 2025
Department of Nuclear Medicine, Zhongnan Hospital of Wuhan University, Wuhan, Hubei Province, China.
Primary splenic angiosarcoma is a rare, aggressive tumor, characterized by rapid metastasis and poor prognosis. Herein, we report a case of 18F-FDG and 68Ga-FAPI-04 PET/CT imaging in a 57-year-old man with primary splenic angiosarcoma. 68Ga-FAPI-04 PET/CT presented much higher uptake in the lesions compared with 18F-FDG PET/CT, showing better diagnostic performance.
View Article and Find Full Text PDF68Ga-FAPI-04 Versus 18F-FDG PET/CT in a Case of Xanthogranulomatous Cholecystitis.
Clin Nucl Med
August 2025
Department of Nuclear Medicine, The Affiliated Hospital of Southwest Medical University.
Xanthogranulomatous cholecystitis (XGC) is an uncommon inflammatory disease of the gallbladder. We report a case of XGC with elevated activity of 18F-FDG and 68Ga-FAPI (fibroblast activating protein inhibitor), which mimics malignancy. Our case suggests that XGS should be considered in the differential diagnosis of cancer-like gallbladder lesions with increased 68Ga-FAPI uptake.
View Article and Find Full Text PDFComparative Utility of 68Ga-FAPI PET/CT and 18F-FDG PET/CT in Assessing Treatment Response in a Case of Metastatic Anal Melanoma With Brain Involvement.
Clin Nucl Med
July 2025
Department of Nuclear Medicine, School of Medicine, Rajaie Cardiovascular, Medical and Research Center.
A 59-year-old man with metastatic melanoma and brain metastases underwent brain radiotherapy. Following treatment, he developed neurological symptoms, prompting further evaluation. To assess the treatment response and possibility of Lutetium-177-FAPI therapy, both 18F-FDG PET/CT and 68Ga-FAPI-46 PET/CT scans were performed.
View Article and Find Full Text PDF[Ga]Ga-FAPI-46 PET accuracy for cancer imaging with histopathology validation: a single-centre, single-arm, interventional, phase 2 trial.
Lancet Oncol
September 2025
Department of Nuclear Medicine, West German Cancer Center, German Cancer Consortium and National Center for Tumor Diseases site, University Hospital Essen, Essen, Germany.
Background: The fibroblast activation protein α (FAP)-directed radiotracer [Ga]Ga-FAPI-46 for PET-CT has shown promising diagnostic accuracy in cancer staging in retrospective studies. We aim to investigate the positive predictive value (PPV) of [Ga]Ga-FAPI-46 PET for detecting FAP-expressing tumours and the potential association between PET radiotracer uptake intensity and immunohistochemical FAP expression.
Methods: This single-centre, single-arm, interventional, phase 2 trial was conducted at the University Hospital Essen, Essen, Germany.